ArticleInternational journal of pancreatology : official journal of the International Association of Pancreatology1991
Growth factors and pancreatic cancer.
Article in International journal of pancreatology : official journal of the International Association of Pancreatology, 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 24 citations in OpenAlex.
- Pancreatic cancer organotypics: High throughput, preclinical models for pharmacological agent evaluation.World journal of gastroenterology · 2014Review
- Molecular biology of pancreatic ductal adenocarcinoma progression: aberrant activation of developmental pathways.Progress in molecular biology and translational science · 2010Review
- Histological complexities of pancreatic lesions from transgenic mouse models are consistent with biological and morphological heterogeneity of human pancreatic cancer.Histology and histopathology · 2007Review
- Pancreatic cancer cells require an EGF receptor-mediated autocrine pathway for proliferation in serum-free conditions.British journal of cancer · 2001Article
- Serum and correspondent tissue measurements of epidermal growth factor (EGF) and epidermal growth factor receptor (EGF-R). Clinical relevance in pancreatic cancer and chronic pancreatitis.International journal of pancreatology : official journal of the International Association of Pancreatology · 1999Article
- Human ductal adenocarcinomas of the pancreas express extracellular matrix proteins.British journal of cancer · 1994Article
- Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin).Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary TractArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Cultured human pancreatic cancer cells produce a number of growth factors, including transforming growth factor-alpha (TGF-alpha). These cells also overexpress the epidermal growth factor (EGF) receptor and exhibit a parallel increase in EGF receptor mRNA levels. TGF-alpha, which binds to the EGF receptor, is more potent than EGF in enhancing the anchorage-independent growth of several pancreatic cancer cell lines, including T3M4 cells. In contrast, EGF is more efficient than TGF-alpha with respect to EGF receptor downregulation and tyrosine phosphorylation in T3M4 cells. Further, T3M4 cells recycle EGF, but markedly degrade TGF-alpha. It is suggested that the production of multiple growth factors, the overexpression of the EGF receptor, the recycling of EGF, and the attenuated ability of TGF-alpha to downregulate the EGF receptor combine to enhance the growth advantage of human pancreatic cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.